Recent Company News

• 12:01 PM ET Apr 08, 2026
  

  Ascendis Pharma to list ordinary shares directly on Nasdaq ($227.41, +6.93)

• 08:06 AM ET Apr 08, 2026
  

  Ascendis Pharma announces new data from week 52 of ongoing COACH trial showed TransCon hGH accelerated TransCon CNP's benefits beyond linear growth in children with achondroplasia ($220.48, 0.00)

• 08:51 AM ET Mar 16, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 05:38 PM ET Mar 16, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 04:03 PM ET Apr 06, 2026
  

  Ascendis Pharma receives orphan drug exclusivity and launches YUVIWEL (Navepegritide) in the United States ($226.69, 0.00)

• 08:34 AM ET Mar 17, 2026
  

  Ascendis Pharma announces positive Week 52 topline results from New InsiGHTS Phase II trial ($231.03, 0.00)

• 08:04 AM ET Mar 16, 2026
  

  New two-year data from pivotal approach trial showing durable benefits of TransCon CNP (navepegritide) in children with achondroplasia shared at ACMG 2026 ($225.98, 0.00)

• 05:07 PM ET Mar 15, 2026
  

  Jefferies initiates ABVX, DSGN; assumes ALNY, ASND, COGT, others